Skip to content
Home » Focus on Atopic Eczema – Anthony Chu, FRCP. Professor of Dermatology

Focus on Atopic Eczema – Anthony Chu, FRCP. Professor of Dermatology

    Atopic eczema is one of the commonest of the inflammatory skin diseases and its incidence is increasing. In a recent epidemiologic study, the worldwide incidence of atopic eczema in children and adolescence was 20% and in the UK the incidence of atopic eczema in adults was 8.1% (1). In about 60% of children with atopic eczema other manifestations of the atopic diathesis are present including allergic rhinitis, asthma and multiple type I allergies (1).

    Pathophysiology of atopic eczema

    It is important to understand the basic pathophysiology of the disease to be able to treat it effectively. This has been detailed in a recent excellent review (2). In atopic eczema, the skin is dry with defective skin barrier function which is considered to be the first step in the development of atopic eczema. Loss of barrier function in the atopic individual is multifactorial with loss of function of filaggrin, a structural protein that is pivotal in the formation of the stratum corneum (3) and a change in composition of stratum corneum lipids due to altered expression of certain enzymes involved their biosynthesis (4). Inflammation in the skin can further alter filaggrin and lipid levels with worsening of xerosis with severity of the eczema (4). 

    Infection/colonisation of atopic eczema by Staphylococcus aureus is important in the development and exacerbation of this disease but is often ignored by those treating this disease. Colonisation of atopic eczema with S aureus is very common and may be related to adhesion factors in the epidermis exposed by barrier dysfunction, deficiency of antimicrobial peptides in the atopic, microbial dysbiosis and over expression of Th2/Th17 cytokines. Colonisation with S aureus leads to further disruption of skin barrier function due to superantigens, enzymes and other factors and superantigens will exacerbate the inflammatory response in the skin. A major recent challenge therapeutically is colonisation by methicillin-resistant S aureus.

    Managing atopic eczema
    Conventional Management

    The majority of patients with atopic eczema have mild to moderate disease which can be treated in the community using conventional treatment i.e. emollients and moisturisers, topical corticosteroids or calcinurin inhibitors and anti-infection agents or antibiotics. Treatment of patients is often, unfortunately, inadequate.of patients with atopic eczema have mild to moderate disease which can be treated in the community using conventional treatment i.e. emollients and moisturisers, topical corticosteroids or calcinurin inhibitors and anti-infection agents or antibiotics. Treatment of patients is often, unfortunately, inadequate.

    Studies have shown that the regular use of moisturisers reduce dryness of the skin and transepidermal water loss and increased the time to flare of the eczema (5). They are also essential when patients are treated with topical corticosteroids as these agents will increase dryness of the skin. Contact allergic dermatitis to substances found in topical treatments including emollients and topical corticosteroids does occur and patch testing should be considered in patients showing worsening of their symptoms despite adequate treatment (6).

    Bleach Baths

    The use of bleach baths has radically changed my management of atopic eczema. Use a teaspoon of household bleach (sodium hypochlorite) with liquid emollient in a baby bath or a dessert spoon full in a normal bath and soak for 15 minutes. I use this daily while the eczema is active then reduce to once or twice a week when the skin is in remission. Bleach baths are anti-microbial and will reduce S aureus level but also have anti-flammatory and anti-pruritic effects. Most reports have used the baths twice weekly but patients tolerate daily baths without problem. The use of bleach baths is controversial and studies have suggested that the benefit is no better than plain water baths when used twice weekly (7) but in my experience bleach baths work very well.

    Coagulase negative Staphylococcus

    Skin commensal bacterial Staphylococcus hominis and Staphylococcus epidermidis produce antimicrobial peptides that can resist S aureus colonisation and studies have shown that transplantation of coagulase negative Staphylococcus onto atopic eczema skin inhibited S aureus (8).

    Probiotics

    The use of probiotics in atopic eczema is controversial. Studies have shown increased permeability of the intestine and reduced skin micobiome diversity in atopic eczema. Probiotics are considered to improve intestinal permeability and modulate the body’s microbiome and immune status. A systemic review and meta-analysis of controlled trials showed some efficacy in reducing inflammation in atopic eczema (9).

    Vitamin D

    Vitamin D in atopic eczema remains controversial. Vitamin D is an immune-modulator. Studies have shown a correlation between low vitamin D levels and atopic eczema severity and studies have shown improvement of atopic eczema with vitamin D supplements in those found to be deficient (10). It is certainly worth checking vitamin D levels in your atopic eczema patient failing on conventional treatment.

    Topical Coal Tar

    Topical coal tar has been used in the treatment of atopic eczema for decades but has largely fallen out of favour due to its smell and messiness. A recent study, however, has shown that its use induces keratinocyte derived antimicrobial proteins and leads to a reduction of Staphylococcus density on the skin (11).

    Systemic Immunosuppressants

    In patients who fail topical treatments, systemic immunosuppressants are used. The most frequently used is methotrexate. A recent study of long-term methotrexate in childhood atopic eczema showed improvement in 83% and hospitalisation for their eczema reduced by 50%. At a median 2 year follow up after stopping treatment 66% were clear or had mild to moderate eczema (12).

    Other systemic immunosuppressant has been successfully used in atopic eczema. Azathioprine was a popular choice but has now been superseded by methotrexate, ciclosporin and mycophenolate mofetil (13).

    New Treatments
    Dupilumab

    Dupilumab is a fully humanised monoclonal antibody that blocks interleukin 4 and interleukin 13 which shows marked and rapid improvement of moderate to severe atopic eczema (14). NICE guidelines published in 2018 are that Dupilumab should be considered in an adult with moderate to sever atopic eczema that has not responded to at least 1 systemic immunosuppressant therapy. The drug should be stopped at 16 weeks if the eczema has not responded adequately. Dupilumab is used subcutaneously at 600mg initially then at 300mg alternate week. The cost of the drug is £27,410 to £28,495 per quality-adjusted life year. Studies have shown its efficacy in children with atopic eczema but it does not yet have a licence for paediatric use.

    This is, as with all biologic agents, an expensive treatment with the potential to be over used given our experience with biologic treatment in psoriasis.

    Crisaborole

    This is a new topical phosphodiesterase 4 inhibitor available in the USA as a 2% ointment for the treatment of mild to moderate atopic eczema. It is not yet licenced for use in UK. Phosphodiesterase type 4 is the primary cAMP metabolizing enzyme involved in the control of activity in inflammatory cells and inhibitors of this enzyme will have an effect in inflammatory dermatosis. Studies have shown good safety and efficacy profile of Crisaborole (15).

    Emerging Treatments

    A number of drugs are in the pipeline. The JAK-STAT inhibitors are the most promising. Biologic agents: IL4/IL13 antagonists lebrikizumab and tralokinumab and IL31Ra antagonist nemolizumab are also under active investigation (16).The JAK-STAT inhibitors are the most promising. Biologic agents: IL4/IL13 antagonists lebrikizumab and tralokinumab and IL31Ra antagonist nemolizumab are also under active investigation (16).

    The Dire State of Dermatology in the UK

    Considering that a high percentage of a GPs work is dermatological, teaching of dermatology in UK medical schools is generally rudimentary or in some schools only an option. Dermatology positions for GP trainees are very few. Of the 738 consultant dermatologist positions in the UK to serve a population of over 60 million, 257 are at present unfilled. There are 237 training positions in dermatology but many will want part time jobs and many consultants are leaving the NHS early due to the changes in the NHS. Given the restriction on what we can provide in the NHS and the threat of dermatology services being put out to tender and taken over by private providers I can fully understand this. The people who suffer are the patients with dermatologic conditions. Few skin diseases are fatal but many have severe impacts on the quality of life of the sufferer and these patients need a good and robust dermatology service.

    References

    1. Kowalska-Oledzka E, Czarnecka , Baran A. Epidemiology in atopic dermatitis in Europe. J Drug Assess 2019; 8:126-128.
    2. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc 2019; 40:84-92
    3. Sandilands A, Sutherland C, Irvine AD, Inwin McLean WH, Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122:1285-94.
    4. Danso M, Boiten W, van Drongelen et al. Althered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci 2017;88:57-66
    5. Pohar R, McCormack S. Emollient treatments for atopic dermatitis: Review of clinical effectiveness, cost-effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health 2019 (CADTH rapid response report: summary with critical appraisal)
    6. Teo Y, McFadden JP, White IR et al. Allergic contact dermatitis in atopic individuals: Results of a 30 year retrospective study. Contact Dermatitis 2019;10.1111/cod. 13363
    7. Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systemic review and meta-analysis. Ann Allergy Asthma Immunol 2017;199:435-440
    8. Nakatsuji T, Chen TH, Narala S et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med 2017; 9:eaah4680
    9. Huang R, Ning H, Shen M et al. Probiotics for treatment of atopic dermatitis in children: a systemic review and meta-analysis of randomised controlled trials. Front Cell Infect Microbiol 2017;7:392
    10. Quirk S, Rainwater E, Shure A, Agrawal DK. Vittamin D in atopic dermatitis, chronic urticaria and allergic contact dermatitis. Expert Rev Clin Immunol 2016;12:839-47.
    11. Smits JPH, Ederveen THA, Rikken G et al. TARgetting the cutaneous microbiota in atopic dermatitis by coal tar via AHA-dependent induction of antimicrobial proteins. J Invest Dermatol 2019;S0022-202X(19)325445-X, doi: 10.1016/j,jid.2019.06.142
    12. Purvis D, Lee M, Agnew K et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health 2019; 10.1111/jpc. 14478.
    13. Phan K, Smith SD.Mycophenolate mofetil and atopic dermatitis: systemic review and meta-analysis. J Dermatolog Treast 2019;:1-5. Doi:10.1080/09546634.2019.1642996.
    14. Beck LA, Thaci D, Hamilton JD et al. Dupilumab treatment in adults with moderate to severe atopic dermatitis. N Engl J Med 2014;371:130-9.
    15. Zane LT, Kircik L, Call R et al. Crisaborole topical ointment in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open label, maximal use systemic exposure study. Paediatr Dermatol 2016;33:380-387.
    16. Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for topic dermatitis, Paediatr Drugs 2019;21:239-260

    Content provided by Anthony Chu, FRCP. Professor of Dermatology.